Industry

Psychedelic treatments for mental health: Is there substance behind the hype?

Psychedelic treatments have been considered in the treatment of mental health since the 1950s, following Albert Hofmann’s development of lysergic…

Yet another clinical hold for Gilead’s magrolimab trials

Gilead Sciences had paused enrolment in the magrolimab solid tumour trials, with the FDA requesting a partial clinical hold on…

Puma Biotechnology begins Phase II trial of lung cancer drug

US-based biopharmaceutical company Puma Biotechnology has initiated a Phase II clinical trial to evaluate alisertib, a monotherapy designed to treat…

How did the pharmaceutical industry treat orphan designated drugs in Q4 2023 filings?

The global pharmaceutical industry experienced a 5% rise in company filings mentions of orphan designated drugs in Q4 2023 compared…

How did the pharmaceutical industry treat virtual care in Q4 2023 filings?

The global pharmaceutical industry experienced a 32% drop in company filings mentions of virtual care in Q4 2023 compared with…

OSE shares pipeline updates and plans Phase III trial for Tedopi

The French company OSE Immunotherapeutics has provided an update for its clinical pipeline, with plans to start a confirmatory Phase…

INmune Bio doses first subject in Phase I/II prostate cancer trial

INmune Bio has dosed the first subject in a Phase I/II trial of new biologic therapy, INKmune, to treat patients…

TiumBio raises $12m to advance clinical pipeline development

South Korean TiumBio has raised KRW20bn ($12m) through stock financing to fund the development of its clinical programmes. The capital…

Aulos to begin Phase II portion of solid tumour therapy trial

Aulos Bioscience has unveiled plans to begin the Phase II portion of its Phase I/II clinical study of human IgG1…

Seagen seeks new approval for Tukysa in HER2+ breast cancer

On 6 December 2023 at the San Antonio Breast Cancer Symposium, the results of the Phase III HER2CLIMB-02 trial were…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close